Hong Kong-listed Genscript Biotech Corporation reported that 91,000 new ordinary shares were issued in April 2026 through the exercise of employee share options. The transaction raised HKD 0.44 million and increased the total issued share count by 0.004 % to 2.19 billion shares.

The additional shares stemmed from the Post-IPO Share Option Scheme. After the exercise, 25.33 million options remain outstanding, while a further 202.74 million shares could still be issued under the scheme.

Authorised capital was unchanged at 5.00 billion ordinary shares with a par value of USD 0.001, equivalent to USD 5.00 million in registered share capital.

The company held no treasury shares and confirmed that the public float continued to meet the Hong Kong Stock Exchange’s 25 % minimum requirement. No warrants, convertible securities, or other equity instruments were outstanding or issued during the month.